222 related articles for article (PubMed ID: 22037875)
1. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.
Zhang Q; Sakamoto K; Liu C; Triplett AA; Lin WC; Rui H; Wagner KU
Cancer Res; 2011 Dec; 71(24):7513-24. PubMed ID: 22037875
[TBL] [Abstract][Full Text] [Related]
2. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells.
Muraoka RS; Lenferink AE; Law B; Hamilton E; Brantley DM; Roebuck LR; Arteaga CL
Mol Cell Biol; 2002 Apr; 22(7):2204-19. PubMed ID: 11884607
[TBL] [Abstract][Full Text] [Related]
3. Combined effect of cyclin D3 expression and abrogation of cyclin D1 prevent mouse skin tumor development.
Wang X; Sistrunk C; Miliani de Marval PL; Kim Y; Rodriguez-Puebla ML
Cell Cycle; 2012 Jan; 11(2):335-42. PubMed ID: 22214766
[TBL] [Abstract][Full Text] [Related]
4. Increasing the low lipid phosphate phosphatase 1 activity in breast cancer cells decreases transcription by AP-1 and expressions of matrix metalloproteinases and cyclin D1/D3.
Tang X; McMullen TPW; Brindley DN
Theranostics; 2019; 9(21):6129-6142. PubMed ID: 31534541
[TBL] [Abstract][Full Text] [Related]
5. Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins.
Chen CS; Lee CH; Hsieh CD; Ho CT; Pan MH; Huang CS; Tu SH; Wang YJ; Chen LC; Chang YJ; Wei PL; Yang YY; Wu CH; Ho YS
Breast Cancer Res Treat; 2011 Jan; 125(1):73-87. PubMed ID: 20229177
[TBL] [Abstract][Full Text] [Related]
6. Prolactin promotes mammary pathogenesis independently from cyclin D1.
Asher JM; O'Leary KA; Rugowski DE; Arendt LM; Schuler LA
Am J Pathol; 2012 Jul; 181(1):294-302. PubMed ID: 22658484
[TBL] [Abstract][Full Text] [Related]
7. Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.
Wani G; Noyes I; Milo GE; D'Ambrosio SM
Mol Med; 1997 Apr; 3(4):273-83. PubMed ID: 9131589
[TBL] [Abstract][Full Text] [Related]
8. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
9. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.
Montañez-Wiscovich ME; Seachrist DD; Landis MD; Visvader J; Andersen B; Keri RA
Oncogene; 2009 Oct; 28(41):3608-18. PubMed ID: 19648968
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Wang LH; Chan JL; Li W
Int J Cancer; 2007 Jul; 121(1):157-64. PubMed ID: 17304506
[TBL] [Abstract][Full Text] [Related]
11. In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53.
Hosokawa Y; Papanikolaou A; Cardiff RD; Yoshimoto K; Bernstein M; Wang TC; Schmidt EV; Arnold A
Transgenic Res; 2001 Oct; 10(5):471-8. PubMed ID: 11708657
[TBL] [Abstract][Full Text] [Related]
12. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells.
Balasenthil S; Sahin AA; Barnes CJ; Wang RA; Pestell RG; Vadlamudi RK; Kumar R
J Biol Chem; 2004 Jan; 279(2):1422-8. PubMed ID: 14530270
[TBL] [Abstract][Full Text] [Related]
13. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
14. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
15. ErbB2 induces Notch1 activity and function in breast cancer cells.
Lindsay J; Jiao X; Sakamaki T; Casimiro MC; Shirley LA; Tran TH; Ju X; Liu M; Li Z; Wang C; Katiyar S; Rao M; Allen KG; Glazer RI; Ge C; Stanley P; Lisanti MP; Rui H; Pestell RG
Clin Transl Sci; 2008 Sep; 1(2):107-15. PubMed ID: 20443831
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 and D3 expression in melanocytic skin lesions.
Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer.
Russell A; Thompson MA; Hendley J; Trute L; Armes J; Germain D
Oncogene; 1999 Mar; 18(11):1983-91. PubMed ID: 10208420
[TBL] [Abstract][Full Text] [Related]
18. Identification of cyclin D1- and estrogen-regulated genes contributing to breast carcinogenesis and progression.
Yang C; Trent S; Ionescu-Tiba V; Lan L; Shioda T; Sgroi D; Schmidt EV
Cancer Res; 2006 Dec; 66(24):11649-58. PubMed ID: 17178859
[TBL] [Abstract][Full Text] [Related]
19. ErbB2 down-regulates microRNA-205 in breast cancer.
Adachi R; Horiuchi S; Sakurazawa Y; Hasegawa T; Sato K; Sakamaki T
Biochem Biophys Res Commun; 2011 Aug; 411(4):804-8. PubMed ID: 21787752
[TBL] [Abstract][Full Text] [Related]
20. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
